Some Press about CTH
Cynapsus Therapeutics Inc. .................. TICKER: CYNAF:OTCQX; CTH:TSX.V ......................... Cynapsus Therapeutics Inc. is a specialty clinical development company. Its lead drug candidate, APL-130277, is the only oral (sublingual-strip) delivery of the only approved rescue therapy for Parkinson's patients who experience daily "off," or freezing episodes. The … read more .................... The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision. ............... Expert Comments: ................ The Life Sciences Report Interview with Stephen Ireland (3/19/14) "Cynapsus Therapeutics Inc. will finish dosing the 25mg strength of APL-130277, then will embark on APL-130277 efficacy studies, the first of which will be in an Apokyn-naïve patient population. . .the company has development options from a regulatory perspective. .................... It can go down a pure bioequivalence pathway and show the sublingual strip formulation has equivalent pharmacokinetics (PK: absorption, distribution, metabolism and excretion) as subcutaneous Apokyn injection, or it can go after superior safety, along with efficacy. ................ Obviously, if Cynapsus can demonstrate superior safety and efficacy, it will put the product in an even stronger position in a market that is already forecast to be in excess of $700M per year. . .positive clinical data will make APL-130277 a very attractive asset for specialty pharma or large pharma, and I expect Cynapsus will be targeted for M&A activity before it gets a chance to commercialize the product. . . More > ................ Daniel Pearlstein, M Partners (3/12/14) "Activity in the neurology space is encouraging for our outlook on Cynapsus Therapeutics Inc. . .we assume a base-case scenario where 30% of Parkinson's disease patients could use APL- 130277. . .investor sentiment is building not only toward drugs that treat the underlying cause of disease but also those that treat the symptoms. .................. We believe Cynapsus is well positioned in light of growing investor interest in the Parkinson's space." .................... Jason Napodano, Seeking Alpha (2/11/14) "Cynapsus Therapeutics Inc. is one of our best ideas for investment in the small-cap biotechnology sector. . .based on the data and market research that we have seen, the company's shares offer a potential 10x increase in returns. . .our work leads us to believe the global market opportunity for APL-130277 at around $724M." .................... Daniel Pearlstein, M Partners (2/7/14) "As Cynapsus Therapeutics Inc. prepares to enter discussions with the FDA, Dr. Judi Weissinger will play a key role in the progression of Cynapsus. .................. Dr. Weissinger formerly spent ten years at the FDA at the director level and would know how to prepare for and interpret guidance from the FDA. She is a consultant. . .who has a wealth of regulatory experience to provide to the company, especially at this stage. . ................... .we are maintaining our Buy recommendation and our 12-month target price of $1.90/share." .................. Daniel Pearlstein, M Partners (1/14/14) "We are initiating coverage of Cynapsus Therapeutics Inc. with a Buy recommendation and a $1.90 twelve-month price target. . .the company's current enterprise value is almost half as much as our estimate of its lead drug candidate's first full year of U.S. sales in 2017. ................. We estimate that the company needs $20–25M to develop its drug up to a new drug application with the FDA and tap into a $2.5B market if approved. ................ The company expects a lucrative exit strategy with an upfront licensing fee, milestone payments, plus sales royalties or outright acquisition within two to three years."